Researchers reported a new cancer vulnerability tied to cholesterol transport enzymes, showing that disrupting PI5P4K-linked cholesterol trafficking can cause a cholesterol “traffic jam” that blocks tumor cell growth. The work in mice and human cancer cells points to lysosome positioning and cholesterol routing as a metabolic control point. A related report framed cholesterol transport enzymes as essential for cancers that rely on lipid uptake and intracellular metabolite routing to support proliferation, including tumor contexts with TP53 alterations. The convergence of these studies reinforces that cholesterol metabolism is not just a biomarker but a handle for therapy design. For drug developers, the practical takeaway is targetable enzymatic control of cholesterol distribution—potentially enabling metabolic inhibitors that starve tumor cells without needing to block upstream dietary inputs.